{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:56:41Z","timestamp":1793120201815,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Joint Fund of Shandong Provincial Natural Science Foundation","award":["ZR2021LSW026"],"award-info":[{"award-number":["ZR2021LSW026"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation, China","doi-asserted-by":"crossref","award":["81872894"],"award-info":[{"award-number":["81872894"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2021A1515220181"],"award-info":[{"award-number":["2021A1515220181"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004241","name":"China Primary Health Care Foundation","doi-asserted-by":"publisher","award":["0013"],"award-info":[{"award-number":["0013"]}],"id":[{"id":"10.13039\/501100004241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2020M672066"],"award-info":[{"award-number":["2020M672066"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Bethune Charitable Foundation","award":["mnzl202016"],"award-info":[{"award-number":["mnzl202016"]}]},{"DOI":"10.13039\/501100018546","name":"Shandong Province Postdoctoral Innovation Project","doi-asserted-by":"crossref","award":["202002010"],"award-info":[{"award-number":["202002010"]}],"id":[{"id":"10.13039\/501100018546","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CSCO-Pilot Cancer Research Foundation","award":["Y-2019AZQN-0039"],"award-info":[{"award-number":["Y-2019AZQN-0039"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Tumor carcinogenesis and progression result from multiple genetic alterations in tumor cells. However, reliable biomarkers for prostate cancer classification remain limited, often leading to either overtreatment or inadequate treatment. Additionally, effective biomarkers for selecting patients who may benefit from immunotherapy are still lacking. Using data from TCGA-PRAD, we established gene selection criteria to develop a gene-based risk score. We identified a novel gene risk panel comprising six genes (<jats:italic>SSTR1<\/jats:italic>, <jats:italic>CA14<\/jats:italic>, <jats:italic>HJURP<\/jats:italic>, <jats:italic>KRTAP5-1<\/jats:italic>, <jats:italic>VGF<\/jats:italic>, and <jats:italic>COMP<\/jats:italic>) for prostate cancer risk classification. Patients in the high-risk group were associated with poor prognosis. The gene panel exhibited significantly enhanced predictive accuracy for progression-free survival compared to conventional clinicopathological parameters, including T stage, N stage, primary Gleason score, and secondary Gleason score. High-risk patients exhibited a higher tumor mutation burden. Notably, immune activity of CD8\u2009+\u2009T cells, NK cells, and the type II IFN response was significantly lower in the high-risk group, indicating a more immunosuppressive environment. Furthermore, a nomogram combining the gene-based risk score with T stage and histological grade was constructed. The expression of genes in the gene-based risk score was further validated using clinical samples, and <jats:italic>VGF<\/jats:italic> was found to play a significant role in prostate cancer progression. The nomogram could serve as a valuable biomarker for distinguishing between high-risk and low-risk of PFS prostate cancer patients and for selecting patients who might benefit from immunotherapy.<\/jats:p>","DOI":"10.1038\/s41598-025-03800-3","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T20:25:24Z","timestamp":1751401524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identification of novel gene-based risk score for prognosis in prostate cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Huangwei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lejia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benkang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sifeng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"6","key":"3800_CR1","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1177\/1557988318798279","volume":"12","author":"HE Taitt","year":"2018","unstructured":"Taitt, H. E. Global trends and prostate cancer: A review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am. J. Mens Health. 12 (6), 1807\u20131823 (2018).","journal-title":"Am. J. Mens Health"},{"issue":"15","key":"3800_CR2","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","volume":"375","author":"JL Donovan","year":"2016","unstructured":"Donovan, J. L. et al. Patient-Reported outcomes after monitoring, surgery, or radiotherapy for prostate Cancer. N Engl. J. Med. 375 (15), 1425\u20131437 (2016).","journal-title":"N Engl. J. Med."},{"issue":"10","key":"3800_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/jnci\/djj190","volume":"98","author":"AJ Stephenson","year":"2006","unstructured":"Stephenson, A. J. et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Natl. Cancer Inst. 98 (10), 715\u2013717 (2006).","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"3800_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2217\/bmm-2017-0321","volume":"12","author":"M Zanaty","year":"2018","unstructured":"Zanaty, M. et al. Prognostic utility of neutrophil-to-lymphocyte and platelets-to-lymphocyte ratio in predicting biochemical recurrence post robotic prostatectomy. Biomark. Med. 12 (8), 841\u2013848 (2018).","journal-title":"Biomark. Med."},{"issue":"5","key":"3800_CR5","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1097\/01.ju.0000091876.13656.2e","volume":"170","author":"JF Ward","year":"2003","unstructured":"Ward, J. F., Blute, M. L., Slezak, J., Bergstralh, E. J. & Zincke, H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J. Urol. 170 (5), 1872\u20131876 (2003).","journal-title":"J. Urol."},{"key":"3800_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.canlet.2017.08.030","volume":"408","author":"S Wang","year":"2017","unstructured":"Wang, S. et al. Roles of RNA methylation by means of N(6)-methyladenosine (m(6)A) in human cancers. Cancer Lett. 408, 112\u2013120 (2017).","journal-title":"Cancer Lett."},{"issue":"17","key":"3800_CR7","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1158\/1078-0432.CCR-16-0903","volume":"22","author":"RM Chabanon","year":"2016","unstructured":"Chabanon, R. M. et al. Mutational landscape and sensitivity to immune checkpoint blockers. Clin. Cancer Res. 22 (17), 4309\u20134321 (2016).","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"3800_CR8","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144 (5), 646\u2013674 (2011).","journal-title":"Cell"},{"issue":"1","key":"3800_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1634\/theoncologist.2019-0176","volume":"25","author":"MA Morse","year":"2020","unstructured":"Morse, M. A., Hochster, H. & Benson, A. Perspectives on treatment of metastatic colorectal Cancer with immune checkpoint inhibitor therapy. Oncologist 25 (1), 33\u201345 (2020).","journal-title":"Oncologist"},{"key":"3800_CR10","first-page":"239","volume":"6","author":"P Bansal","year":"2016","unstructured":"Bansal, P., Osman, D., Gan, G. N., Simon, G. R. & Boumber, Y. Recent advances in immunotherapy in metastatic NSCLC. Front. Oncol. 6, 239 (2016).","journal-title":"Front. Oncol."},{"issue":"4","key":"3800_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1634\/theoncologist.2018-0084","volume":"24","author":"DL Suzman","year":"2019","unstructured":"Suzman, D. L. et al. FDA approval summary: Atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for Cisplatin-Containing chemotherapy. Oncologist 24 (4), 563\u2013569 (2019).","journal-title":"Oncologist"},{"issue":"8","key":"3800_CR12","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/annonc\/mdy232","volume":"29","author":"AR Hansen","year":"2018","unstructured":"Hansen, A. R. et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann. Oncol. 29 (8), 1807\u20131813 (2018).","journal-title":"Ann. Oncol."},{"issue":"1","key":"3800_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","volume":"35","author":"TM Beer","year":"2017","unstructured":"Beer, T. M. et al. Randomized, Double-Blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic Chemotherapy-Naive Castration-Resistant prostate Cancer. J. Clin. Oncol. 35 (1), 40\u201347 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"2\u20133","key":"3800_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12026-014-8516-1","volume":"58","author":"S Bhattacharya","year":"2014","unstructured":"Bhattacharya, S. et al. ImmPort: disseminating data to the public for the future of immunology. Immunol. Res. 58 (2\u20133), 234\u2013239 (2014).","journal-title":"Immunol. Res."},{"issue":"7","key":"3800_CR15","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43 (7), e47 (2015).","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"3800_CR16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16 (5), 284\u2013287 (2012).","journal-title":"OMICS"},{"issue":"D1","key":"3800_CR17","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53 (D1), D672\u2013D677 (2025).","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"3800_CR18","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward Understanding the origin and evolution of cellular organisms. Protein Sci. 28 (11), 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"issue":"1","key":"3800_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28 (1), 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"3800_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-018-1002-1","volume":"37","author":"Y He","year":"2018","unstructured":"He, Y., Jiang, Z., Chen, C. & Wang, X. Classification of triple-negative breast cancers based on Immunogenomic profiling. J. Exp. Clin. Cancer Res. 37 (1), 327 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"W1","key":"3800_CR21","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li, T. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48 (W1), W509\u2013W514 (2020).","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"3800_CR22","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0896-6273(00)80806-5","volume":"23","author":"S Hahm","year":"1999","unstructured":"Hahm, S. et al. Targeted deletion of the Vgf gene indicates that the encoded secretory peptide precursor plays a novel role in the regulation of energy balance. Neuron 23 (3), 537\u2013548 (1999).","journal-title":"Neuron"},{"issue":"45","key":"3800_CR23","doi-asserted-by":"publisher","first-page":"12156","DOI":"10.1523\/JNEUROSCI.1898-07.2007","volume":"27","author":"S Thakker-Varia","year":"2007","unstructured":"Thakker-Varia, S. et al. The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus. J. Neurosci. 27 (45), 12156\u201312167 (2007).","journal-title":"J. Neurosci."},{"issue":"11","key":"3800_CR24","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1158\/0008-5472.CAN-16-3168","volume":"77","author":"W Hwang","year":"2017","unstructured":"Hwang, W. et al. Expression of neuroendocrine factor VGF in lung Cancer cells confers resistance to EGFR kinase inhibitors and triggers Epithelial-to-Mesenchymal transition. Cancer Res. 77 (11), 3013\u20133026 (2017).","journal-title":"Cancer Res."},{"issue":"6","key":"3800_CR25","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68 (6), 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"3800_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70 (1), 7\u201330 (2020).","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"3800_CR27","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMra1701695","volume":"378","author":"O Sartor","year":"2018","unstructured":"Sartor, O. & de Bono, J. S. Metastatic prostate Cancer. N Engl. J. Med. 378 (7), 645\u2013657 (2018).","journal-title":"N Engl. J. Med."},{"issue":"4","key":"3800_CR28","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1056\/NEJMra021562","volume":"349","author":"WG Nelson","year":"2003","unstructured":"Nelson, W. G., De Marzo, A. M. & Isaacs, W. B. Prostate cancer. N Engl. J. Med. 349 (4), 366\u2013381 (2003).","journal-title":"N Engl. J. Med."},{"issue":"10013","key":"3800_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","volume":"387","author":"G Attard","year":"2016","unstructured":"Attard, G. et al. Prostate cancer. Lancet 387 (10013), 70\u201382 (2016).","journal-title":"Lancet"},{"issue":"6","key":"3800_CR30","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41419-021-03870-x","volume":"12","author":"W Lai","year":"2021","unstructured":"Lai, W. et al. HJURP promotes proliferation in prostate cancer cells through increasing CDKN1A degradation via the GSK3beta\/JNK signaling pathway. Cell. Death Dis. 12 (6), 583 (2021).","journal-title":"Cell. Death Dis."},{"key":"3800_CR31","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.12659\/MSM.906647","volume":"24","author":"L Li","year":"2018","unstructured":"Li, L., Li, X., Meng, Q., Khan, A. Q. & Chen, X. Increased expression of holliday Junction-Recognizing protein (HJURP) as an independent prognostic biomarker in Advanced-Stage serous ovarian carcinoma. Med. Sci. Monit. 24, 3050\u20133055 (2018).","journal-title":"Med. Sci. Monit."},{"issue":"3","key":"3800_CR32","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.molonc.2014.11.002","volume":"9","author":"R Montes de Oca","year":"2015","unstructured":"Montes de Oca, R. et al. The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma. Mol. Oncol. 9 (3), 657\u2013674 (2015).","journal-title":"Mol. Oncol."},{"issue":"6","key":"3800_CR33","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00432-018-2626-4","volume":"144","author":"TT Liu","year":"2018","unstructured":"Liu, T. T. et al. Cartilage oligomeric matrix protein is a prognostic factor and biomarker of colon cancer and promotes cell proliferation by activating the Akt pathway. J. Cancer Res. Clin. Oncol. 144 (6), 1049\u20131063 (2018).","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"9","key":"3800_CR34","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1007\/s00464-019-07185-z","volume":"34","author":"VN Nfonsam","year":"2020","unstructured":"Nfonsam, V. N. et al. Cartilage oligomeric matrix protein (COMP) promotes cell proliferation in early-onset colon cancer tumorigenesis. Surg. Endosc. 34 (9), 3992\u20133998 (2020).","journal-title":"Surg. Endosc"},{"key":"3800_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.matbio.2018.11.007","volume":"81","author":"KS Papadakos","year":"2019","unstructured":"Papadakos, K. S. et al. Cartilage oligomeric matrix protein initiates cancer stem cells through activation of Jagged1-Notch3 signaling. Matrix Biol. 81, 107\u2013121 (2019).","journal-title":"Matrix Biol."},{"issue":"1","key":"3800_CR36","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1186\/s12885-016-2969-7","volume":"16","author":"SR Modarai","year":"2016","unstructured":"Modarai, S. R., Opdenaker, L. M., Viswanathan, V., Fields, J. Z. & Boman, B. M. Somatostatin signaling via SSTR1 contributes to the quiescence of colon cancer stem cells. BMC Cancer. 16 (1), 941 (2016).","journal-title":"BMC Cancer"},{"issue":"2","key":"3800_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/ijc.33988","volume":"151","author":"E Diaz de la Guardia-Bolivar","year":"2022","unstructured":"Diaz de la Guardia-Bolivar, E., Barrios-Rodriguez, R., Zwir, I., Jimenez-Moleon, J. J. & Del Val, C. Identification of novel prostate cancer genes in patients stratified by Gleason classification: role of antitumoral genes. Int. J. Cancer. 151 (2), 255\u2013264 (2022).","journal-title":"Int. J. Cancer"},{"key":"3800_CR38","doi-asserted-by":"publisher","first-page":"106709","DOI":"10.1016\/j.intimp.2020.106709","volume":"86","author":"C Luo","year":"2020","unstructured":"Luo, C., Chen, J. & Chen, L. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer. Int. Immunopharmacol. 86, 106709 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"3800_CR39","doi-asserted-by":"publisher","first-page":"4861570","DOI":"10.1155\/2017\/4861570","volume":"2017","author":"M Janiczek","year":"2017","unstructured":"Janiczek, M. et al. Immunotherapy as a promising treatment for prostate cancer: A systematic review. J. Immunol. Res. 2017, 4861570 (2017).","journal-title":"J. Immunol. Res."},{"issue":"3","key":"3800_CR40","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1111\/cas.13932","volume":"110","author":"M Nishio","year":"2019","unstructured":"Nishio, M. et al. KEYNOTE-025: phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer. Cancer Sci. 110 (3), 1012\u20131020 (2019).","journal-title":"Cancer Sci."},{"issue":"2","key":"3800_CR41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","volume":"152","author":"A Varga","year":"2019","unstructured":"Varga, A. et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol. Oncol. 152 (2), 243\u2013250 (2019).","journal-title":"Gynecol. Oncol."},{"issue":"22","key":"3800_CR42","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic Non-Small-Cell lung Cancer. N Engl. J. Med. 378 (22), 2078\u20132092 (2018).","journal-title":"N Engl. J. Med."},{"issue":"19","key":"3800_CR43","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont, A. M. M. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl. J. Med. 378 (19), 1789\u20131801 (2018).","journal-title":"N Engl. J. Med."},{"issue":"7378","key":"3800_CR44","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480 (7378), 480\u2013489 (2011).","journal-title":"Nature"},{"issue":"26","key":"3800_CR45","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl. J. Med. 366 (26), 2443\u20132454 (2012).","journal-title":"N Engl. J. Med."},{"issue":"3","key":"3800_CR46","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.seminoncol.2015.02.004","volume":"42","author":"S Bracarda","year":"2015","unstructured":"Bracarda, S. et al. Immunologic checkpoints Blockade in renal cell, prostate, and urothelial malignancies. Semin Oncol. 42 (3), 495\u2013505 (2015).","journal-title":"Semin Oncol."},{"issue":"26","key":"3800_CR47","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 Blockade in tumors with Mismatch-Repair deficiency. N Engl. J. Med. 372 (26), 2509\u20132520 (2015).","journal-title":"N Engl. J. Med."},{"issue":"19","key":"3800_CR48","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R. J. et al. Nivolumab versus everolimus in advanced Renal-Cell carcinoma. N Engl. J. Med. 373 (19), 1803\u20131813 (2015).","journal-title":"N Engl. J. Med."},{"issue":"10031","key":"3800_CR49","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (10031), 1909\u20131920 (2016).","journal-title":"Lancet"},{"issue":"5","key":"3800_CR50","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis, E. S. et al. Pembrolizumab for Treatment-Refractory metastatic Castration-Resistant prostate cancer: multicohort, Open-Label phase II KEYNOTE-199 study. J. Clin. Oncol. 38 (5), 395\u2013405 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"3800_CR51","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15 (7), 700\u2013712 (2014).","journal-title":"Lancet Oncol."},{"issue":"8","key":"3800_CR52","doi-asserted-by":"publisher","first-page":"e1466768","DOI":"10.1080\/2162402X.2018.1466768","volume":"7","author":"SE Park","year":"2018","unstructured":"Park, S. E. et al. Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer. Oncoimmunology 7 (8), e1466768 (2018).","journal-title":"Oncoimmunology"},{"issue":"2","key":"3800_CR53","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ccell.2019.01.011","volume":"35","author":"MD Hellmann","year":"2019","unstructured":"Hellmann, M. D. et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in Small-Cell lung Cancer. Cancer Cell. 35 (2), 329 (2019).","journal-title":"Cancer Cell."},{"key":"3800_CR54","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3389\/fonc.2019.01161","volume":"9","author":"Y Wu","year":"2019","unstructured":"Wu, Y. et al. The predictive value of tumor mutation burden on efficacy of immune checkpoint inhibitors in cancers: A systematic review and Meta-Analysis. Front. Oncol. 9, 1161 (2019).","journal-title":"Front. Oncol."},{"issue":"6","key":"3800_CR55","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","volume":"170","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber, E. R. & Lowe, S. W. Putting p53 in context. Cell 170 (6), 1062\u20131078 (2017).","journal-title":"Cell"},{"issue":"12","key":"3800_CR56","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","volume":"23","author":"ZY Dong","year":"2017","unstructured":"Dong, Z. Y. et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 Blockade immunotherapy in lung adenocarcinoma. Clin. Cancer Res. 23 (12), 3012\u20133024 (2017).","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"3800_CR57","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1158\/1078-0432.CCR-18-0163","volume":"24","author":"J Biton","year":"2018","unstructured":"Biton, J. et al. TP53, STK11, and EGFR mutations predict tumor immune profile and the response to Anti-PD-1 in lung adenocarcinoma. Clin. Cancer Res. 24 (22), 5710\u20135723 (2018).","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"3800_CR58","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","volume":"5","author":"F Skoulidis","year":"2015","unstructured":"Skoulidis, F. et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 5 (8), 860\u2013877 (2015).","journal-title":"Cancer Discov"},{"issue":"15","key":"3800_CR59","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1158\/0008-5472.CAN-19-0761","volume":"79","author":"Q Zhang","year":"2019","unstructured":"Zhang, Q. et al. Inhibition of ATM increases interferon signaling and sensitizes pancreatic Cancer to immune checkpoint Blockade therapy. Cancer Res. 79 (15), 3940\u20133951 (2019).","journal-title":"Cancer Res."},{"issue":"4","key":"3800_CR60","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrc2618","volume":"9","author":"JA Joyce","year":"2009","unstructured":"Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer. 9 (4), 239\u2013252 (2009).","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"3800_CR61","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.canlet.2013.01.042","volume":"341","author":"ML Taddei","year":"2013","unstructured":"Taddei, M. L., Giannoni, E., Comito, G. & Chiarugi, P. Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett. 341 (1), 80\u201396 (2013).","journal-title":"Cancer Lett."},{"issue":"11","key":"3800_CR62","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.it.2003.09.007","volume":"24","author":"PA Albertsson","year":"2003","unstructured":"Albertsson, P. A. et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol. 24 (11), 603\u2013609 (2003).","journal-title":"Trends Immunol."},{"issue":"17","key":"3800_CR63","doi-asserted-by":"publisher","first-page":"e89829","DOI":"10.1172\/jci.insight.89829","volume":"1","author":"R Mandal","year":"2016","unstructured":"Mandal, R. et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 1 (17), e89829 (2016).","journal-title":"JCI Insight"},{"issue":"6","key":"3800_CR64","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/1074-7613(94)90087-6","volume":"1","author":"AS Dighe","year":"1994","unstructured":"Dighe, A. S., Richards, E., Old, L. J. & Schreiber, R. D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1 (6), 447\u2013456 (1994).","journal-title":"Immunity"},{"issue":"13","key":"3800_CR65","doi-asserted-by":"publisher","first-page":"7556","DOI":"10.1073\/pnas.95.13.7556","volume":"95","author":"DH Kaplan","year":"1998","unstructured":"Kaplan, D. H. et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U S A. 95 (13), 7556\u20137561 (1998).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"7","key":"3800_CR66","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1530\/ERC-18-0552","volume":"26","author":"M Ji","year":"2019","unstructured":"Ji, M. et al. LncRNA H19 binds VGF and promotes pNEN progression via PI3K\/AKT\/CREB signaling. Endocr. Relat. Cancer. 26 (7), 643\u2013658 (2019).","journal-title":"Endocr. Relat. Cancer"},{"issue":"1","key":"3800_CR67","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s13046-023-02894-9","volume":"42","author":"W Dai","year":"2023","unstructured":"Dai, W. et al. Hedgehog-Gli1-derived Exosomal circ-0011536 mediates peripheral neural remodeling in pancreatic cancer by modulating the miR-451a\/VGF axis. J. Exp. Clin. Cancer Res. 42 (1), 329 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"3800_CR68","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12022-013-9277-4","volume":"25","author":"L Annaratone","year":"2014","unstructured":"Annaratone, L. et al. Search for neuro-endocrine markers (chromogranin A, synaptophysin and VGF) in breast cancers. An integrated approach using immunohistochemistry and gene expression profiling. Endocr. Pathol. 25 (3), 219\u2013228 (2014).","journal-title":"Endocr. Pathol."},{"issue":"6","key":"3800_CR69","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","volume":"173","author":"MR Cooperberg","year":"2005","unstructured":"Cooperberg, M. R. et al. The university of California, San Francisco Cancer of the prostate risk assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J. Urol. 173 (6), 1938\u20131942 (2005).","journal-title":"J. Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03800-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03800-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03800-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T22:03:06Z","timestamp":1751407386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03800-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3800"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03800-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of the Shandong University School of Clinical Medicine. 10 human PCa tissues were collected at the Qilu Hospital of Shandong University. Informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22128"}}